LAV Biosciences Fund V, L.P. 4
4 · Terns Pharmaceuticals, Inc. · Filed Feb 9, 2021
Insider Transaction Report
Form 4
LAV Biosciences Fund V, L.P.
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2][F8]2021-02-09+1,392,857→ 1,392,857 total(indirect: See footnotes) - Conversion
Common Stock
[F1][F3][F8]2021-02-09+696,428→ 696,428 total(indirect: See footnotes) - Conversion
Common Stock
[F4][F6][F5][F8]2021-02-09+1,286,698→ 1,286,698 total(indirect: See footnotes) - Conversion
Common Stock
[F6][F7][F8]2021-02-09+1,405,583→ 1,405,583 total(indirect: See footnotes) - Conversion
Series A Preferred Stock
[F1][F2][F8]2021-02-09−1,392,857→ 0 total(indirect: See footnotes)→ Common Stock (1,392,857 underlying) - Conversion
Series A Preferred Stock
[F1][F3][F8]2021-02-09−696,428→ 0 total(indirect: See footnotes)→ Common Stock (696,428 underlying) - Conversion
Series B Preferred Stock
[F4][F5][F8]2021-02-09−952,380→ 0 total(indirect: See footnotes)→ Common Stock (952,380 underlying) - Conversion
Series C Preferred Stock
[F6][F5][F8]2021-02-09−334,318→ 0 total(indirect: See footnotes)→ Common Stock (334,318 underlying) - Conversion
Series C Preferred Stock
[F6][F7][F8]2021-02-09−1,405,583→ 0 total(indirect: See footnotes)→ Common Stock (1,405,583 underlying)
Footnotes (8)
- [F1]Each share of Series A Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F2]Shares held by Hopewell Resources Holdings Limited.
- [F3]Shares held by Oriental Spring Venture Limited.
- [F4]Each share of Series B Preferred Stock automatically converted on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F5]Shares held by LAV Aqua Limited.
- [F6]Each share of Series C Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F7]Shares held by LAV Biosciences Fund V, L.P.
- [F8]LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.